Vy le
Family Medicine · Penn Yan, NYNPI 1134674443
Payments from drug & device makers
Across 502 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Pfizer$931
- Boehringer Ingelheim$659
- Lilly USA, LLC$500
- GSK$470
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,007100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 67 | $1,647 |
| Novo Nordisk | 83 | $1,320 |
| Pfizer | 61 | $931 |
| Boehringer Ingelheim | 34 | $659 |
| Lilly USA, LLC | 29 | $500 |
| GSK | 30 | $470 |
| AbbVie(2 entities) | 21 | $465 |
| Amgen | 23 | $397 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $301 |
| Merck | 14 | $224 |
| Johnson & Johnson(2 entities) | 11 | $204 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $187 |
| Exact Sciences | 9 | $185 |
| Bayer | 9 | $172 |
| Amarin Pharma, Inc. | 8 | $147 |
| Phathom Pharmaceuticals, Inc. | 6 | $135 |
| Teva Pharmaceuticals USA, Inc. | 7 | $132 |
| Astellas Pharma US Inc | 6 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $104 |
| Sanofi-aventis U.S. LLC | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Paratek Pharmaceuticals, Inc. | 5 | $71 |
| Boston Scientific | 2 | $70 |
| Insulet Corporation | 3 | $63 |
| Corcept Therapeutics | 3 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $53 |
| Novartis | 3 | $42 |
| Abbott | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,013 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $95,835 |
| OzempicSemaglutide | 64 | $93,429 |
| TrulicityDulaglutide | 53 | $77,378 |
| JardianceEmpagliflozin | 47 | $58,989 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $55,689 |
| Xigduo XrDapaglifloz Propaned/Metformin | 41 | $40,807 |
| XareltoRivaroxaban | 18 | $26,514 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $23,330 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $20,751 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $13,053 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $10,278 |
| VascepaIcosapent Ethyl | 15 | $8,997 |
| MyrbetriqMirabegron | 21 | $8,347 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $7,015 |
| Atorvastatin Calcium | 406 | $4,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $931 | $95,83579 claims |
| Novo NordiskOzempic | $1,320 | $93,42964 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $659 | $89,33483 claims |
| Lilly USA, LLCTrulicity | $500 | $77,37853 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $470 | $75,512122 claims |
| Johnson & JohnsonXarelto | $204 | $26,51418 claims |
| AstraZenecaBreztri Aerosphere | $1,647 | $20,75131 claims |
| Astellas Pharma US IncMyrbetriq | $108 | $8,34721 claims |
| AbbVieSynthroid | $465 | $2,56639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Penn Yan
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.